AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 65 filers reported holding AVROBIO INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $6,125,000 | -47.4% | 689,002 | -24.9% | 0.22% | -46.9% |
| Q1 2021 | $11,640,000 | -17.3% | 917,222 | -9.1% | 0.42% | -10.1% |
| Q4 2020 | $14,068,000 | +34.0% | 1,009,212 | +25.1% | 0.47% | +8.1% |
| Q3 2020 | $10,501,000 | -27.7% | 806,521 | -3.1% | 0.43% | -31.8% |
| Q2 2020 | $14,527,000 | +17.5% | 832,474 | +4.8% | 0.63% | -11.5% |
| Q1 2020 | $12,364,000 | -6.4% | 794,603 | +21.1% | 0.72% | +28.1% |
| Q4 2019 | $13,211,000 | +42.2% | 656,306 | -0.3% | 0.56% | +28.6% |
| Q3 2019 | $9,292,000 | -4.8% | 658,056 | +9.7% | 0.43% | +10.7% |
| Q2 2019 | $9,756,000 | -28.0% | 599,998 | -2.3% | 0.39% | -28.9% |
| Q1 2019 | $13,548,000 | +113.8% | 614,408 | +61.4% | 0.55% | +76.6% |
| Q4 2018 | $6,338,000 | -67.7% | 380,636 | +0.6% | 0.31% | -56.7% |
| Q3 2018 | $19,626,000 | +186.7% | 378,374 | +57.9% | 0.72% | +179.5% |
| Q2 2018 | $6,845,000 | – | 239,660 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |